SIB provides expert support in research data management internationally thanks to various large-scale European collaborations involving academic institutions as well as the industry, notably led by the Vital-IT Computational Biology group. These projects tackle major public health issues such as diabetes, obesity, cancer or rheumatic diseases. Our role spans from acting as Data Coordination Centre to developing innovative solutions to leverage sensitive data and fostering the adoption of FAIR principles.
A key actor for large European public-private partnerships tackling major public health issues
As a Data Coordination Centre or as a provider of cutting-edge bioinformatics expertise (e.g. integrative data analysis, database and web development), SIB is a key player in a dozen of large European projects looking at harnessing the power of big data to fight public health issues. Explore some of them below and find out what expertise we offer in each.
Diabetes and complications
Innovative solutions for dealing with sensitive data under GDPR
Building on open-source technology, SIB has implemented and further developed federated analysis systems as part of three major European projects (Innovative Medicines Initiative - IMI) in the fields of diabetes research (RHAPSODY and BEAt-DKD) and obesity (SOPHIA).
The special feature of these systems is that they enable statistical analysis and machine learning to be carried out remotely on several clinical databases connected in a network but not shared so as to maintain their confidentiality.
As part of these projects, SIB has worked with academic and industrial partners to set up three systems that connect more than 30 clinical studies.
An example of federated analysis applied to diabetes research:
Joining forces to ensure that life science data are FAIR
SIB is actively contributing to the European IMI FAIRPlus project, which provides guidelines and tools to easily ensure that life sciences data is FAIR (Findable, Accessible, Interoperable and Reusable). Our role here is to contribute to the evaluation and prioritization of IMI datasets for FAIRification and to FAIR guidelines and recommendations. As for all IMIs, the project brings together partners from academia, SMEs and pharmaceutical companies (e.g. AstraZaneca AB, Eli Lilly and Company Ltd., Novartis Pharma AG) to enable wider adoption of best practises in life science data management.
The work carried out as part of this project benefits the entire life sciences community and helps to maximise public investment in research.
SIB is also a partner in the ELIXIR Converge project, working with other data managers and trainers across Europe to provide tools and training for data management in the life sciences.
Banner image credit: Christian Lue on Unsplash